PMID- 26029452
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150601
LR  - 20220331
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 6
IP  - 3
DP  - 2015 Jun
TI  - Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients 
      with varying liver dysfunction.
PG  - 259-67
LID - 10.3978/j.issn.2078-6891.2015.005 [doi]
AB  - BACKGROUND: Sorafenib is the only FDA-approved systemic therapy for advanced 
      hepatocellular carcinoma (HCC). In clinical practice, dose reductions are often 
      required, although there are limited efficacy data related to dose modifications. 
      Given the prevalence of HCC in South Texas, we assessed the efficacy and safety 
      of sorafenib therapy in relation to dose and Child Pugh (CP) score. METHODS: A 
      retrospective analysis was done of advanced HCC patients, starting sorafenib at 
      400 mg twice daily, or at physician discretion at 400 mg daily, with the goal of 
      titrating to twice daily. Overall survival (OS) and progression-free survival 
      (PFS) were assessed. RESULTS: Among 107 patients, median OS (mOS) was 10.2 
      months; median PFS (mPFS) was 5.2 months. mOS for sorafenib 400 mg/day was 6.6 
      vs. 800 mg/day was 12.8 months [hazard ratio (HR), 0.59; P=0.04]; mPFS was 3.5 
      vs. 5.9 months, respectively (HR, 0.66; P=0.07). For Child Pugh A class (CP-A) 
      patients, mOS was 15.8 months for 400 mg/day vs. 12.8 months for 800 mg/day (HR, 
      1.48; P=0.35); mPFS was 9.0 vs. 5.9 months, respectively (HR, 1.23; P=0.56). For 
      Child Pugh B class (CP-B) patients, mOS was 5.0 months for 400 mg/day vs. 11.2 
      months for 800 mg/day (HR, 0.33; P=0.002); mPFS was 2.1 vs. 5.6 months, 
      respectively (HR, 0.41; P=0.006). No differences in adverse events (AEs) were 
      observed in CP-A vs. CP-B. CONCLUSIONS: Patients with CP-A or CP-B advanced HCC 
      should be offered sorafenib at 400 mg twice daily with optimal management of AEs 
      in order to improve survival.
FAU - Al-Rajabi, Raed
AU  - Al-Rajabi R
AD  - University of Texas Health Science Center San Antonio, San Antonio, TX 78229, 
      USA.
FAU - Patel, Sukeshi
AU  - Patel S
AD  - University of Texas Health Science Center San Antonio, San Antonio, TX 78229, 
      USA.
FAU - Ketchum, Norma S
AU  - Ketchum NS
AD  - University of Texas Health Science Center San Antonio, San Antonio, TX 78229, 
      USA.
FAU - Jaime, Nicole A
AU  - Jaime NA
AD  - University of Texas Health Science Center San Antonio, San Antonio, TX 78229, 
      USA.
FAU - Lu, Ting-Wei
AU  - Lu TW
AD  - University of Texas Health Science Center San Antonio, San Antonio, TX 78229, 
      USA.
FAU - Pollock, Brad H
AU  - Pollock BH
AD  - University of Texas Health Science Center San Antonio, San Antonio, TX 78229, 
      USA.
FAU - Mahalingam, Devalingam
AU  - Mahalingam D
AD  - University of Texas Health Science Center San Antonio, San Antonio, TX 78229, 
      USA.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC4397242
OTO - NOTNLM
OT  - Child Pugh (CP) cirrhosis
OT  - Liver cancer
OT  - hepatobiliary
OT  - metastatic
EDAT- 2015/06/02 06:00
MHDA- 2015/06/02 06:01
PMCR- 2015/06/01
CRDT- 2015/06/02 06:00
PHST- 2015/01/08 00:00 [received]
PHST- 2015/01/13 00:00 [accepted]
PHST- 2015/06/02 06:00 [entrez]
PHST- 2015/06/02 06:00 [pubmed]
PHST- 2015/06/02 06:01 [medline]
PHST- 2015/06/01 00:00 [pmc-release]
AID - jgo-06-03-259 [pii]
AID - 10.3978/j.issn.2078-6891.2015.005 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2015 Jun;6(3):259-67. doi: 
      10.3978/j.issn.2078-6891.2015.005.